Cypress Capital’s Anika Therapeutics ANIK Stock Holding History

Cypress Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7	Closed	–	–	189
2021 Q2	$0	Hold	7	–	–	﹤0.01%	82
2021 Q1	$0	Buy	+7	New	+$266	﹤0.01%	110

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

Cypress Capital's ANIK Position: Q3 2021 in Review

Cypress Capital sold out of Anika Therapeutics (ANIK) in Q3 2021, closing a stake of 7 shares.

Cypress Capital first reported a position in ANIK in Q1 2021 and held it in 2 quarters. The position peaked at $0 in Q2 2021. 131 funds tracked by Wall St. Rank hold ANIK as of Q3 2021.

Cypress Capital reported no remaining Anika Therapeutics position as of Q3 2021 after selling out during the quarter.
Cypress Capital sold 7 Anika Therapeutics shares in Q3 2021.
Cypress Capital first reported a position in Anika Therapeutics in Q1 2021 and held it in 2 quarters.
Cypress Capital's Anika Therapeutics position peaked at $0 in Q2 2021.
131 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2021.

Based on Cypress Capital's 13F filing for Q3 2021, filed 10 Feb 2022.